Abstract
Human immunodeficiency virus-infected women (n=16) received indinavir (800 mg three times a day) plus zidovudine plus lamivudine from 14 to 28 weeks of gestation to 12 weeks postpartum. Two women and eight infants experienced grade 3 or 4 toxicities that were possibly treatment related. Indinavir area under the plasma concentration-time curve was 68% lower antepartum versus postpartum, suggesting increased intestinal and/or hepatic CYP3A activity during pregnancy.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adult
-
Cytochrome P-450 CYP3A / metabolism
-
Female
-
HIV Infections / drug therapy*
-
HIV Protease Inhibitors* / adverse effects
-
HIV Protease Inhibitors* / pharmacokinetics
-
HIV-1*
-
Humans
-
Indinavir* / adverse effects
-
Indinavir* / pharmacokinetics
-
Infant, Newborn
-
Liver / metabolism
-
Male
-
Maternal-Fetal Exchange
-
Pregnancy
-
Pregnancy Complications, Infectious / drug therapy*
Substances
-
HIV Protease Inhibitors
-
Indinavir
-
Cytochrome P-450 CYP3A